The Cooper Companies, Inc. (LON:0I3I)
| Market Cap | 8.58B -29.8% |
| Revenue (ttm) | 3.03B +5.7% |
| Net Income | 292.58M -3.4% |
| EPS | 1.46 -3.0% |
| Shares Out | n/a |
| PE Ratio | 29.34 |
| Forward PE | 12.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,610 |
| Average Volume | 991 |
| Open | 58.91 |
| Previous Close | 59.91 |
| Day's Range | 58.91 - 59.94 |
| 52-Week Range | 58.60 - 89.11 |
| Beta | 0.89 |
| RSI | 26.88 |
| Earnings Date | Jun 4, 2026 |
About The Cooper Companies
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women’s health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cor... [Read more]
Financial Performance
In fiscal year 2025, The Cooper Companies's revenue was $4.09 billion, an increase of 5.06% compared to the previous year's $3.90 billion. Earnings were $374.90 million, a decrease of -4.44%.
Financial numbers in USD Financial StatementsNews
Cooper Companies appoints Envista CEO Paul Keel to board
Cooper Companies (COO) announced that its board of directors has appointed Paul Keel as an independent director, effective July 1. Keel has also been appointed to serve on the audit…
CooperCompanies Appoints Paul Keel to its Board of Directors
SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an in...
CooperCompanies Announces Release Date for Second Quarter 2026
SAN RAMON, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report second quarter 2026 financial results on Th...
CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹
New sustainability platform reflects company's commitment to responsible sourcing, moreefficient manufacturing, and offsetting a portion of plastic footprint *†1 ROCHESTER, N.Y., April 9, 2026 /PRNews...
Cooper Companies price target lowered to $80 from $87 at Citi
Citi lowered the firm’s price target on Cooper Companies (COO) to $80 from $87 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology…
Cooper Companies price target raised to $101 from $99 at Needham
Needham raised the firm’s price target on Cooper Companies (COO) to $101 from $99 and keeps a Buy rating on the shares. The company’s Q1 results marked a solid start…
Cooper Companies price target lowered to $87 from $88 at Citi
Citi lowered the firm’s price target on Cooper Companies (COO) to $87 from $88 and keeps a Neutral rating on the shares.
Cooper Companies price target raised to $103 from $98 at Barclays
Barclays raised the firm’s price target on Cooper Companies (COO) to $103 from $98 and keeps an Overweight rating on the shares. The firm says the company posted improving sequential…
The Cooper Companies Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and earnings growth, driven by product launches, operational efficiencies, and robust cash flow. Guidance for earnings and free cash flow was raised, with continued momentum expected in the Americas and EMEA, while Asia Pac is set to recover in the second half.
CooperCompanies Announces First Quarter 2026 Results
SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended Janua...
Cooper Companies downgraded to Neutral from Buy at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Issie Kirby downgraded Cooper Companies (COO) to Neutral from Buy with a price target of $85, down from $92. The firm says that after a…
CooperCompanies Announces Release Date for First Quarter 2026
SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, M...
Cooper Companies price target lowered to $99 from $100 at Needham
Needham lowered the firm’s price target on Cooper Companies (COO) to $99 from $100 and keeps a Buy rating on the shares. Ahead of Sebela’s mid-2026 Miudella launch, the firm…
Cooper Companies price target raised to $98 from $97 at Barclays
Barclays raised the firm’s price target on Cooper Companies (COO) to $98 from $97 and keeps an Overweight rating on the shares. The firm made minor changes to the company’s…
The Cooper Companies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Operating in growing contact lens and fertility markets, the company is focused on organic growth, product innovation, and capital efficiency. Strategic review is underway to assess business structure, with strong free cash flow and market share gains expected.
Cooper Companies price target raised to $73 from $71 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Cooper Companies (COO) to $73 from $71 and keeps a Sell rating on the shares. After a year when fundamentals diverged from…
'Forgotten' stocks that could be 2026 powerhouses
Boyar Research is out with its "Forgotten Forty" list, comprising 40 overlooked stocks that are most likely to outperform this year. Boyar Research president, Jonathan Boyar, joins Market Catalysts ho...
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on We...
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company's Board of Directors (the “Board”) has appointed ...
Cooper Companies CEO buys $808K in common stock
In a regulatory filing, Cooper Companies (COO) disclosed that its CEO Albert White bought 10k shares of common stock on December 16th in a total transaction size of $808K. Published…
Cooper Companies price target raised to $71 from $64 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Cooper Companies (COO) to $71 from $64 and keeps a Sell rating on the shares. Cooper reported a relatively in line Q4,…
The Cooper Companies Earnings Call Transcript: Q4 2025
Q4 revenue hit a record $1.065B, up 4.6% year-over-year, with strong MyDay and MiSight growth offsetting softness in China. Fiscal 2026 guidance calls for 4.5–5.5% organic growth and $575–$625M free cash flow, with continued focus on share repurchases and a formal strategic review underway.
Cooper Companies initiates strategic review; shares jump
Medical device maker Cooper Companies said it is initiating a formal strategic review aimed at identifying opportunities to enhance long-term shareholder value, sending shares up 11.7% in extended tra...
CooperCompanies Announces New Chair of the Board and Strategic Review
SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed c...
CooperCompanies Announces Fourth Quarter and Full Year 2025 Results
SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full ye...